The incidence of postmenopausal diseases increases with the age of women. In this review, we introduce cell therapy products, a new treatment for postmenopausal osteoporosis, which often occurs in postmenopausal women. We also figure out the trends of research on cell therapy products and emphasize the necessity and importance of this research for researchers and postmenopausal women. Finally, we suggest the direction for improvement of postmenopausal osteoporosis and research on cell therapy products. We investigated which medication have been used so far. We also examined the development and technical problems of technologies that are currently in use. (J Menopausal Med 2016;22:71-75)
Introduction
The average life expectancy has been increasing constantly due to technical developments in medicine, industry, and science. The average life expectancy appears to be longer in women than in men. The average life expectancy of Korean women was 85.5 years in 2014, which was 0.84 years higher than in 2012. Consequently, the incidence of diseases related to aging in women and interest in studying and finding treatments for these diseases have been also increasing. 1 Especially, postmenopausal osteoporosis, the main disease related to aging in women, is a highrisk disease that decreases bone strength and makes it easier for patients' bones to be fractured. 2 Currently, most medications for postmenopausal osteoporosis suppress activity of osteoclasts and cause adverse effects. 3 
Technologies and Principles of Cell Therapy Products in Postmenopausal Osteoporosis
Most studies on stem cell applications likely aim to advance fundamental knowledge. However, phased studies that aim to develop a cell therapy product are in progress and bring them to the market. These cells can be isolated not only from bone marrow, but also from peripheral blood and umbilical cord blood. 12, 13 Studies of cell surface antibody suggested that mesenchymal stem cells could be purified by using magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS).
However, more studies of representative surface antigens are needed. 14 
Lack of clinical trials
There have been animal studies that reported transplantation of stem cells originated from bone marrow to treat musculoskeletal system defects such as spondylodesis and arthritis, and to reconstruct skull bone defects, local defects of joint cartilage, and tendon defects. 13 However, there are no clinical studies about stem cell transplantation from bone marrow in humans, except for the purpose of bone defect reconstruction and in patients with avascular necrosis of femoral head. 12 Therefore, further clinical studies in humans are required.
Summary
Postmenopausal osteoporosis is a high-risk disease that decreases bone strength and makes it easier for pa- Once further studies are performed, it would be easier to apply these technologies to postmenopausal patients with gynecological and endocrine-related diseases including osteoporosis. 18, 19 Consequently, the quality of life in elderly women as well as postmenopausal women will improve. We perform this study so that scientists as well as physicians pay attention to cell therapy technology and applying cell therapy technology to menopausal medicine.
